Multiple myeloma disrupts the TRANCE/ osteoprotegerin cytokine axis to trigger bone destruction and promote tumor progression. - Wikidata - thesis-toulmin - TriplyDB

Multiple myeloma disrupts the TRANCE/ osteoprotegerin cytokine axis to trigger bone destruction and promote tumor progression.

Multiple myeloma disrupts the TRANCE/ osteoprotegerin cytokine axis to trigger bone destruction and promote tumor progression.

http://www.wikidata.org/entity/Q33944735

about

Osteoimmunology: interactions of the bone and immune system Hypercalcemia in metastatic GIST caused by systemic elevated calcitriol: a case report and review of the literature Role of osteocytes in multiple myeloma bone disease Receptor activator of NF-κB ligand induces cell adhesion and integrin α2 expression via NF-κB in head and neck cancers.The role of the BMP signaling antagonist noggin in the development of prostate cancer osteolytic bone metastasis Mechanism of Action of Bortezomib and the New Proteasome Inhibitors on Myeloma Cells and the Bone Microenvironment: Impact on Myeloma-Induced Alterations of Bone Remodeling The secret life of a megakaryocyte: emerging roles in bone marrow homeostasis control Increased osteoclastogenesis in mice lacking the carcinoembryonic antigen-related cell adhesion molecule 1 Zoledronic acid preserves bone structure and increases survival but does not limit tumour incidence in a prostate cancer bone metastasis model Treatment of multiple myeloma bone disease: experimental and clinical data.Myeloma plasma cells alter the bone marrow microenvironment by stimulating the proliferation of mesenchymal stromal cells.Osteoclast-gene expression profiling reveals osteoclast-derived CCR2 chemokines promoting myeloma cell migration.Transplantation of mesenchymal stem cells overexpressing RANK-Fc or CXCR4 prevents bone loss in ovariectomized mice.Osteoblastogenesis and tumor growth in myeloma.Advances in the understanding of myeloma bone disease and tumour growth.Multiple myeloma: changes in serum C-terminal telopeptide of collagen type I and bone-specific alkaline phosphatase can be used in daily practice to detect imminent osteolysis The critical role of IL-34 in osteoclastogenesis Safety concern between autologous fat graft, mesenchymal stem cell and osteosarcoma recurrence.Tracking human multiple myeloma xenografts in NOD-Rag-1/IL-2 receptor gamma chain-null mice with the novel biomarker AKAP-4 Novel therapeutic targets in myeloma bone disease.Multiple myeloma mesenchymal stromal cells: Contribution to myeloma bone disease and therapeutics Bone disease in multiple myeloma: pathophysiology and management.How B cells influence bone biology in health and disease Inhibition of TACE activity enhances the susceptibility of myeloma cells to TRAIL.Heparanase enhances local and systemic osteolysis in multiple myeloma by upregulating the expression and secretion of RANKL First-line treatment with bortezomib rapidly stimulates both osteoblast activity and bone matrix deposition in patients with multiple myeloma, and stimulates osteoblast proliferation and differentiation in vitro.Embelin suppresses osteoclastogenesis induced by receptor activator of NF-κB ligand and tumor cells in vitro through inhibition of the NF-κB cell signaling pathway Novel targeted deregulation of c-Myc cooperates with Bcl-X(L) to cause plasma cell neoplasms in mice.Soluble rank ligand produced by myeloma cells causes generalised bone loss in multiple myeloma Inhibition of BDNF in multiple myeloma blocks osteoclastogenesis via down-regulated stroma-derived RANKL expression both in vitro and in vivo.A prospective evaluation of the biochemical, metabolic, hormonal and structural bone changes associated with bortezomib response in multiple myeloma patients.Involvement of integrins alpha(3)beta(1) and alpha(5)beta(1) and glycoprotein IIb in megakaryocyte-induced osteoblast proliferation.Glycosaminoglycans modulate RANKL-induced osteoclastogenesis Inhibitory effects of osteoblasts and increased bone formation on myeloma in novel culture systems and a myelomatous mouse model The phenotypic plasticity of myeloma plasma cells as expressed by dedifferentiation into an immature, resilient, and apoptosis-resistant phenotype Insulin like growth factor binding protein 7 (IGFBP7) expression is linked to poor prognosis but may protect from bone disease in multiple myeloma.New approaches in the immunotherapy of haematological malignancies.LIGHT/TNFSF14 increases osteoclastogenesis and decreases osteoblastogenesis in multiple myeloma-bone disease.Interpreting the molecular biology and clinical behavior of multiple myeloma in the context of global gene expression profiling.CYP2C8 gene polymorphism and bisphosphonate-related osteonecrosis of the jaw in patients with multiple myeloma.

P2860

Q24655113-99A66F23-5BEF-4B95-BBD6-3B06CACF5753 Q26779429-867453E5-0C25-4739-81F2-B771F31A1FF0 Q26992195-326D1323-79EB-4633-A31B-606E181B5B8E Q27326719-BB0E54B0-1DCB-461C-9003-B3125786FE83 Q27437809-A6818DC9-7EA9-475F-A5CA-8A4D8F9D7375 Q28082335-B44E5285-43DD-4C6D-9179-1F0BE712A041 Q28082685-1E2F9D56-669D-47DC-812C-1BA4B4CA1C63 Q28513481-86D82B17-3AF0-4D42-B3B1-8F53AF2C06CB Q28744548-BF84293B-520E-49F0-9100-6F34C1EEC71C Q30868833-A39CA87A-B382-49F8-AFF5-86FFD3307595 Q33558170-44011805-53D3-4C6C-BC68-92254429A9A6 Q33564854-336BA22C-52D3-4A20-8B81-8E67A40440D4 Q33713146-5D5F772A-3C9B-4E45-8033-EB33960E1AB8 Q33768466-F8B068E3-C620-4C33-B883-036C12C82424 Q33829022-7366D39F-FE16-4520-9D0B-7EA246F31A7A Q33854017-D017AFFE-F206-4076-9351-8D11EBB9C465 Q33873578-236FE0E7-9DDE-4D3C-AB5C-8DB7BA613DEE Q33900327-FBCB8D54-1E20-4664-9505-5947FEB71609 Q34020937-9679920B-8A56-46C1-9E21-C721C7AB1204 Q34025065-3F9FFC31-E045-4D66-BE06-E62AB2DD3AB2 Q34038854-70D418FE-ACD4-482E-932C-6D39DBED3886 Q34045789-4EC15E7A-8DF3-4C9B-B266-DA16F4A72AD4 Q34137037-6F41CEE4-7757-4449-8752-2C36C3BF5C46 Q34184457-2425BD60-FA10-496D-8565-6747D887F79B Q34267974-CC6D9430-ED7B-49C7-B77F-445789455251 Q34269238-F5B0943D-7627-4F84-AF49-C93E5C87779C Q34279869-801862E3-DB51-4C63-A6EA-16082A03F90B Q34380431-9621B38A-70C5-4318-A49F-904740BEFCE4 Q34404651-F4D1862D-71B9-43AB-ACA7-CEFB94C27A76 Q34450321-A135BFFA-E7F1-4AB5-9BB6-1EB80D2B0A10 Q34543089-A128C903-A758-41DD-B454-2E94BBC4677C Q34581935-6CF329B7-A56C-4076-A4AC-4D53F7CA39D6 Q34982927-DB3FFC66-B533-41A3-8D86-E5013CBBEBA7 Q35070415-148BB928-3BAD-41C2-91ED-047E3151E6DC Q35070420-ACF2FF23-4EFA-4DF2-BB0E-DCB42CDD2637 Q35097641-612C9E32-F18F-499C-BF7C-5ACCE5F64A4A Q35106657-C15AB3D4-10E3-416E-8EB9-BC3A8D36A5A0 Q35149611-81A1C11C-3DE8-4A1C-A0A1-3F0A7E16D253 Q35170930-B58D5DC8-2DA7-47F0-B080-0140ADF4E243 Q35266066-D01D8267-5352-49B2-AA40-96DE8516162E

P2860

Multiple myeloma disrupts the TRANCE/ osteoprotegerin cytokine axis to trigger bone destruction and promote tumor progression.

http://www.wikidata.org/entity/Q33944735

description

2001 nî lūn-bûn

@nan

2001 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած

@hyw

2001 թվականի սեպտեմբերին հրատարակված գիտական հոդված

@hy

2001年の論文

@ja

2001年論文

@yue

2001年論文

@zh-hant

2001年論文

@zh-hk

2001年論文

@zh-mo

2001年論文

@zh-tw

2001年论文

@wuu

name

Multiple myeloma disrupts the ...... and promote tumor progression.

@ast

Multiple myeloma disrupts the ...... and promote tumor progression.

@en

type

label

Multiple myeloma disrupts the ...... and promote tumor progression.

@ast

Multiple myeloma disrupts the ...... and promote tumor progression.

@en

prefLabel

Multiple myeloma disrupts the ...... and promote tumor progression.

@ast

Multiple myeloma disrupts the ...... and promote tumor progression.

@en

P1433

Q33944735-C0F6DBA4-3E8A-4A24-9BDF-530B4037353E

P1476

Q33944735-9906EFC6-54C8-4A2B-A426-B93E3285C1C0

P2093

Q33944735-17EF134F-2110-40DA-9C1E-C885369E926D

Q33944735-1C6E8C62-23E7-4603-A040-6B7AFE9FCF22

Q33944735-34DD77AE-D8A4-4907-8780-B2C76A4B72F3

Q33944735-61298E56-0AA2-4877-A94B-436984B0389C

Q33944735-9B5A187D-2BB8-4AAD-811C-791FE0554B0A

Q33944735-A464C99D-3DD3-494F-9F7F-B25A885B7129

Q33944735-E123C860-0486-40B3-B1FB-A30BB327DD5D

Q33944735-E97C4FCF-93A7-4F1E-A4D9-8900EB5645E2

Q33944735-F7936D4D-D25D-4E2D-9472-7366F1B231BC

P2860

Q33944735-0314C82D-3AE2-42B5-B13B-0CBF31EC2920

Q33944735-20531B45-9E36-4B40-989B-979BEED209E9

Q33944735-20E6C05B-EB37-4746-BA69-811AAAAFC5A9

Q33944735-2431E604-1C39-4B69-B1E3-D1D2FB9FF4C9

Q33944735-257724E8-075A-435F-90EC-405709C21430

Q33944735-2CAD1018-3EE6-4A2E-99F5-6125C5E9E05A

Q33944735-2FB037C4-1598-47C8-A785-ADD331140063

Q33944735-3B6AC37A-68AE-4DC6-B074-0D65A7654770

Q33944735-3CA225E9-ED87-4E13-B567-778E5A7CBF84

Q33944735-3D641309-58AF-41D2-BCE4-0CE302DE54ED

P304

Q33944735-DD7AD873-D4AB-4241-8DD4-386DCCBD0E82

P31

Q33944735-6265F214-3CA0-40AA-AB83-6037AAB36BE2

P356

Q33944735-0850A0A7-0B90-4E44-9D80-14B9CC19FEAD

P407

Q33944735-7F554716-9075-42C4-ABDF-F5DBEE2D06F3

P433

Q33944735-8A548BDC-199A-4E3A-A37D-D6FF64F4BA84

P478

Q33944735-E7EEDE80-FB20-4AC7-A7AD-59A56CB26AC5

P577

Q33944735-4EEF637A-2478-4097-AE13-FCCFBD332CB1

P5875

Q33944735-795793C1-6559-4AA0-8D1B-7BBD60556005

P698

Q33944735-88585A77-6AF5-4975-92A0-18D60F9529C8

P932

Q33944735-8737672F-CDCB-4FF9-A0A3-A6FFFA359E48

P356

P1433

Proceedings of the National Academy of Sciences of the United States of America

P1476

Multiple myeloma disrupts the ...... and promote tumor progression.

@en

P2093

B R Wong

http://www.w3.org/2001/XMLSchema#string

D F Liau

http://www.w3.org/2001/XMLSchema#string

E M Sordillo

http://www.w3.org/2001/XMLSchema#string

J Epstein

http://www.w3.org/2001/XMLSchema#string

J Michaeli

http://www.w3.org/2001/XMLSchema#string

N Colman

http://www.w3.org/2001/XMLSchema#string

R N Pearse

http://www.w3.org/2001/XMLSchema#string

S Yaccoby

http://www.w3.org/2001/XMLSchema#string

Y Choi

http://www.w3.org/2001/XMLSchema#string

P2860

Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation

Osteoprotegerin: a novel secreted protein involved in the regulation of bone density

Isolation of a novel cytokine from human fibroblasts that specifically inhibits osteoclastogenesis

A homologue of the TNF receptor and its ligand enhance T-cell growth and dendritic-cell function

RANK is essential for osteoclast and lymph node development

osteoprotegerin-deficient mice develop early onset osteoporosis and arterial calcification

Osteoclast differentiation factor is a ligand for osteoprotegerin/osteoclastogenesis-inhibitory factor and is identical to TRANCE/RANKL

Evidence for a role of a tumor necrosis factor-alpha (TNF-alpha)-converting enzyme-like protease in shedding of TRANCE, a TNF family member involved in osteoclastogenesis and dendritic cell survival

Macrophage-inflammatory protein-1alpha regulates preosteoclast differentiation in vitro

OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph-node organogenesis

P304

11581-11586

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1073/PNAS.201394498

http://www.w3.org/2001/XMLSchema#string

P407

P433

20

http://www.w3.org/2001/XMLSchema#string

P478

98

http://www.w3.org/2001/XMLSchema#string

P577

2001-09-18T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

11784520

http://www.w3.org/2001/XMLSchema#string

P698

11562486

http://www.w3.org/2001/XMLSchema#string

P932

58772

http://www.w3.org/2001/XMLSchema#string